Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Eli Lilly and Company
Eli Lilly and Company
Incyte Corporation
Verastem, Inc.
Astellas Pharma Inc
Wake Forest University Health Sciences
AstraZeneca
University Health Network, Toronto
The Netherlands Cancer Institute
Eikon Therapeutics
Incyte Corporation
M.D. Anderson Cancer Center
AstraZeneca
Centre Francois Baclesse
BeiGene
Dana-Farber Cancer Institute
Checkpoint Therapeutics, Inc.
Phanes Therapeutics
AstraZeneca
Deciphera Pharmaceuticals, LLC
Jules Bordet Institute
Genentech, Inc.
Actuate Therapeutics Inc.
Taiho Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
G1 Therapeutics, Inc.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OHSU Knight Cancer Institute
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Shanghai Henlius Biotech
OncoSec Medical Incorporated
Nektar Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
The Netherlands Cancer Institute
Fudan University
Shanghai Jiao Tong University School of Medicine
G1 Therapeutics, Inc.
Actuate Therapeutics Inc.
NextCure, Inc.
AbbVie
AbbVie
Novartis
Mereo BioPharma
UNC Lineberger Comprehensive Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris